DiCE Molecules Revenue and Competitors
Estimated Revenue & Valuation
- DiCE Molecules's estimated annual revenue is currently $17.2M per year.
- DiCE Molecules's estimated revenue per employee is $155,000
- DiCE Molecules's total funding is $187.4M.
Employee Data
- DiCE Molecules has 111 Employees.
- DiCE Molecules grew their employee count by 25% last year.
DiCE Molecules's People
| Name | Title | Email/Phone |
|---|
DiCE Molecules Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 26 | -16% | N/A | N/A |
What Is DiCE Molecules?
DiCE Molecules is a privately-held company focused on the development of small molecule compounds that act by unlocking protein-protein interfaces that have been intractable targets for orally bioavailable drugs. Utilizing its unique approach, DiCE can amplify the strongest potential drug candidates and, by combining massive diversity with amplification and selection, substantially increase the probability of success.
keywords:N/A
$187.4M
Total Funding
111
Number of Employees
$17.2M
Revenue (est)
25%
Employee Growth %
N/A
Valuation
N/A
Accelerator
DiCE Molecules News
... life sciences and venture capital companies, including Dice Molecules, Adverum Biotechnologies, One Ventures, and Blade Therapeutics.
DiCE Molecules, a San Francisco, CA-based biopharmaceutical company leveraging its proprietary DNA-encoded library platform to discover and develop next-generation therapeutics in immunology and other therapeutic areas, completed its $60m Series C-1 financing. The round was led by RA Capital Ma ...
DiCE Molecules, a biopharmaceutical company leveraging its proprietary DNA-encoded library platform to discover and develop next-generation therapeutics in immunology and other therapeutic areas, today announced the completion of its $60 million Series C-1 financing. The financing was led by RA ...
RA Capital Management has led an $80 million Series C for Dice Molecules, a biopharmaceutical company that focuses on immunology. The company plans to use the funding in part to advance clinical trials of one of its oral medicines. Select Additional Investors Northpond Ventures, New Leaf Ventu ...
Other Companies in Redwood City
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $17.2M | 111 | -7% | N/A |
#2 | $19.4M | 114 | 6% | N/A |
#3 | $30.8M | 114 | -7% | N/A |
#4 | $15M | 117 | 5% | N/A |
#5 | $16.5M | 118 | -1% | $30M |